Publicaciones en colaboración con investigadores/as de Hospital Universitario 12 de Octubre (141)

2024

  1. Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting

    International Journal of Dermatology, Vol. 63, Núm. 4, pp. 503-511

  2. Family Planning Concerns Among Women With Psoriasis: A Descriptive, Cross-Sectional, Multicenter Study

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 1, pp. 10-20

  3. No tuberculosis reactivations in psoriasis patients initiating new generation biologics despite untreated latent tuberculosis infection: Multicenter case series of 35 patients

    Journal of the European Academy of Dermatology and Venereology

  4. Pityriasis Rubra Pilaris: A Multicentric Case Series of 65 Spanish Patients

    Actas Dermo-Sifiliograficas

  5. Psoriasis Severity, Health-Related Quality of Life, Work Productivity, and Activity Impairments Among Patients With Moderate to Severe Psoriasis Receiving Systemic Treatment: Real-World Data From Clinical Practice in Spain

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 1, pp. 1-9

  6. Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study

    Actas Dermo-Sifiliograficas

  7. Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry

    British Journal of Dermatology, Vol. 190, Núm. 3, pp. 355-363

2023

  1. Anti-Interleukin 23 Biologic Are Mostly Effective and Safe in Psoriatic Patients Who Failed Anti-Interleukin 17. A Real-Life, Retrospective 52-Week Experience

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 4, pp. 363-365

  2. Anti-Interleukin 23 Biologic Are Mostly Effective and Safe in Psoriatic Patients Who Failed Anti-Interleukin 17. A Real-Life, Retrospective 52-Week Experience

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 4, pp. T363-T365

  3. Apremilast treatment of plaque psoriasis (PsO) after systemic therapy in Spanish clinical practice: Data from the APPROPRIATE study

    JEADV Clinical Practice, Vol. 2, Núm. 3, pp. 488-501

  4. Comorbilidades en las psoriasis pustulosas

    Piel, Vol. 38, Núm. 8, pp. 525-529

  5. Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study

    BMJ open, Vol. 13, Núm. 7, pp. e075197

  6. Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population

    Australasian Journal of Dermatology, Vol. 64, Núm. 4, pp. e317-e326

  7. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 12, pp. 2517-2525

  8. Erythrodermic Psoriasis Has Become Less Frequent: Results From the Biobadaderm Registry

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 4, pp. T366-T369

  9. Generalized Pustular Psoriasis: A Review on Clinical Characteristics, Diagnosis, and Treatment

    Dermatology and Therapy, Vol. 13, Núm. 3, pp. 673-688

  10. Generalized pustular psoriasis: practical recommendations for Spanish primary care and emergency physicians

    Postgraduate Medicine, Vol. 135, Núm. 8, pp. 766-774

  11. High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting

    International Journal of Dermatology

  12. NanoString analysis of mycosis fungoides reveals individual molecular identity

    British Journal of Dermatology

  13. Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice

    Journal of the European Academy of Dermatology and Venereology